Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 18, 2026, 8:38 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 985–1008 of 10,729 matching trials from the live ClinicalTrials.gov search.
Conditions
Acute Biphenotypic Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, B-Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Hematologic and Lymphocytic Disorder, Hematopoietic Cell Transplantation Recipient, Myelodysplastic Syndrome, Primary Myelofibrosis, Secondary Myelofibrosis, T-Cell Non-Hodgkin Lymphoma, Thrombocytopenia, Venous Thromboembolism
Interventions
Platelet Transfusion
Biological
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Seattle, Washington
Completed Phase 1 Interventional Results available

A Study of SHP655 (rADAMTS13) in Sickle Cell Disease

NCT03997760
Conditions
Sickle Cell Disease
Interventions
TAK-755, Placebo
Drug · Other
Lead sponsor
Shire
Industry
Eligibility
18 Years to 65 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
14
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Aurora, Colorado + 11 more
Conditions
Acute Myeloid Leukemia
Interventions
Azacitidine, Venetoclax
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 59 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Aurora, Colorado
Conditions
Sickle Cell Disease
Interventions
Ticagrelor, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
2 Years to 17 Years
Enrollment
193 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
7
States / cities
Fort Lauderdale, Florida • Miami, Florida • Chicago, Illinois + 4 more
Conditions
Multiple Myeloma
Interventions
Bortezomib 1 mg/m2, Bortezomib 1.3 mg/m2, Bortezomib 1.6 mg/m2, Melphalan
Drug
Lead sponsor
Hackensack Meridian Health
Other
Eligibility
18 Years to 76 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Hackensack, New Jersey
Conditions
Multiple Myeloma
Interventions
Elranatamab (PF-06863135)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
187 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
37
States / cities
Beverly Hills, California • Irvine, California • Los Angeles, California + 17 more
Conditions
Acute Myeloid Leukemia
Interventions
Azacitidine, Tagraxofusp-erzs
Drug · Biological
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
2
States / cities
Los Angeles, California • San Francisco, California
Conditions
Chronic Myeloproliferative Disorders, Infection, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
Interventions
amphotericin B deoxycholate, nystatin
Drug
Lead sponsor
Aronex Pharmaceuticals
Industry
Eligibility
2 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2007
U.S. locations
59
States / cities
Phoenix, Arizona • Fort Smith, Arkansas • Little Rock, Arkansas + 47 more
Conditions
Lymphoma, Mantle Cell Lymphoma, Indolent Lymphoma, SLL
Interventions
rituximab, bortezomib, cladribine
Drug
Lead sponsor
University of Arizona
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2018
U.S. locations
1
States / cities
Tucson, Arizona
Terminated Phase 2 Interventional Results available

Weight-based Dosing in Hemophilia A

NCT02586012
Conditions
Hemophilia
Interventions
rFVIII
Drug
Lead sponsor
Craig Seaman
Other
Eligibility
18 Years and older · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Conditions
Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Blastic Phase Chronic Myelogenous Leukemia, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Relapsing Chronic Myelogenous Leukemia, Secondary Acute Myeloid Leukemia
Interventions
cytarabine, triapine, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Sickle Cell Disease, Pharmacokinetics
Interventions
L-glutamine
Drug
Lead sponsor
Emmaus Medical, Inc.
Industry
Eligibility
5 Years and older
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Cincinnati, Ohio
Conditions
Hemophilia A, Hemophilia B
Interventions
Testing of hepatic AAV Vector integration
Diagnostic Test
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Male only
Enrollment
173 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2040
U.S. locations
15
States / cities
Rancho Cordova, California • Sacramento, California • San Francisco, California + 6 more
Conditions
Leukemia, Lymphoma
Interventions
filgrastim, rituximab, cyclophosphamide, cytarabine, dexamethasone, doxorubicin hydrochloride, etoposide, ifosfamide, leucovorin calcium, methotrexate, prednisone, vincristine sulfate, Allopurinol
Biological · Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
16 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2014
U.S. locations
31
States / cities
San Diego, California • Lewes, Delaware • Newark, Delaware + 25 more
Conditions
Acute Lymphoblastic Leukemia
Interventions
Hyper CVAD Protocol (Standard of Care Multi-Agent Chemotherapy), Calaspargase Pegol, Rituximab
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years to 50 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Tampa, Florida
Conditions
Multiple Myeloma
Interventions
Pomalidomide, Bortezomib, Dexamethasone
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
559 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
92
States / cities
Mobile, Alabama • Tucson, Arizona • Berkeley, California + 68 more
Conditions
Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Kidney Cancer, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Neuroblastoma, Ovarian Cancer, Testicular Germ Cell Tumor
Interventions
recombinant interleukin-12
Biological
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
1
States / cities
Indianapolis, Indiana
Recruiting No phase listed Observational Accepts healthy volunteers

Comprehensive HHT Outcomes Registry of the United States (CHORUS)

NCT06259292
Conditions
Hereditary Hemorrhagic Telangiectasia, Arteriovenous Malformations, Telangiectasia, Epistaxis, GastroIntestinal Bleeding, Cerebral Arteriovenous Malformations, Vascular Malformation
Interventions
Not listed
Lead sponsor
Cure HHT
Other
Eligibility
Not listed
Enrollment
10,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2033
U.S. locations
16
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 13 more
Conditions
Multiple Myeloma
Interventions
ASP7487, Velcade, Dexamethasone
Drug
Lead sponsor
University Health Network, Toronto
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
2
States / cities
Atlanta, Georgia • Chicago, Illinois
Not listed No phase listed Observational Accepts healthy volunteers

300 Antibody Diagnostic Test Kit

NCT01646411
Conditions
Acute Bacterial Infections, Acute Viral Infections
Interventions
Not listed
Lead sponsor
The Plasma Source
Industry
Eligibility
18 Years to 70 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Southampton, Pennsylvania
Conditions
Malignant Solid Tumor, Lymphomas, Multiple Myeloma
Interventions
AV-299, AV-299 + erlotinib
Biological
Lead sponsor
AVEO Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
3
States / cities
Scottsdale, Arizona • Columbus, Ohio • San Antonio, Texas
Conditions
Acute Myelogenous Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, Chronic Myelogenous Leukemia
Interventions
KW-2449
Drug
Lead sponsor
Kyowa Kirin, Inc.
Industry
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
4
States / cities
Baltimore, Maryland • Princeton, New Jersey • New York, New York + 1 more
Conditions
Cancer, Solid Tumor, Hematologic Malignancy
Interventions
Not listed
Lead sponsor
Community Cancer Care
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
3
States / cities
Indianapolis, Indiana • Martinsville, Indiana
Conditions
Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell
Interventions
JNJ-64264681
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
New York, New York